What you need to know:
1. The analyst attributes Exact’s growth largely to the increased sales of Cologuard. Sales took off after Exact entered into a marketing and promotional partnership with Pfizer in 2018.
2. Those sales — as well as Exact’s developmental work on liquid biopsy tests with Rochester, Minn.-based Mayo Clinic — have some analysts believing the company could be an acquisition target. However, its most likely suitor, Pfizer, recently made a $10.6 billion acquisition, which leads Motley Fool analysts to speculate that any acquisition talks are on hold.
3. Analysts believe Cologuard will pass $1 billion in sales in 2020, which is fueling the company’s high valuation.
4. However, Exact’s monopolistic grasp on the market, and in turn its valuation, could fall off if competitors succeed in bringing tests to the market.
More articles on gastroenterology:
3 things to know about outpatient cervical disc replacement
10 things to know about spine surgery for ASCs in 2019
Outpatient revision minimally invasive lumbar decompression: 4 notes on ASC vs. HOPD
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.